1. Japan Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Nichi-Iko Pharmaceutical Co., Ltd.

Nichi-Iko Pharmaceutical Co., Ltd.

NHKFF
Nichi-Iko Pharmaceutical Co., Ltd.US flagOther OTC
0.36
USD
- -
- -
Nichi-Iko Pharmaceutical Co., Ltd.
NHKFF
(Other OTC)

Recent

price

0.36

P/E

ratio

- -

div

yld

- -

ROIC.AI

2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
FRC
1,054.26
1,397.85
1,777.39
1,986.1
1,941.22
- -
2,370.52
1,739.04
2,127.94
2,400.94
2,653.3
2,917.65
2,613.65
2,972.73
2,935.13
179,060,000,000
182,880,000,000
Revenue per Share
85.38
112.3
121.98
119.32
97.6
- -
129.47
77
110.42
184.52
85.25
142.94
107.69
80.28
-65.17
-104,984,000,000
-160,438,000,000
Basic EPS, GAAP
2.56
-123.25
44.34
-49.18
-149.06
- -
58.87
12.34
258.53
-66.61
-290.44
81.92
141.72
-1.55
-220.21
-40,061,000,000
-43,517,000,000
Free Cash Flow per Basic Share
11.04
28.88
27.99
28.51
29.87
- -
27.01
21.3
24.61
27.55
32.94
29.86
27.2
29.95
29.91
644,000,000
2,000,000
Dividend per Share
403.34
462.69
553.8
686.19
829.86
- -
616.65
470.97
556.21
1,039.03
1,155.9
1,273.36
1,229.64
1,262.51
1,156.82
-29,682,000,000
-101,192,000,000
Book Value per Share
436.24
441.1
503.64
693.01
984.07
- -
1,121.82
1,051.21
1,169.76
1,251.14
-132.36
57.94
419.05
253.99
153.09
-44,315,000,000
-71,953,000,000
Tangible Book Value per Share
31
31
31
32
40
40
40
60
60
60
56
56
64
64
64
- -
- -
Basic Weighted Avg Shares
32,317
42,850
54,824
64,344
77,729
- -
93,906
103,614
127,038
143,534
149,263
164,717
166,592
190,076
188,218
179,060
182,880
Sales/Revenue/Turnover
12.9
12.08
11.39
11.03
9.64
- -
8.76
7.13
7.57
9
4.28
6.25
4.94
1.51
0.06
-61.46
-90.74
Operating Margin (%)
798
1,065
1,746
2,922
4,336
- -
4,771
6,023
4,994
5,355
7,065
8,659
9,401
11,871
13,217
12,653
10,335
Depreciation Expense
2,617
3,442
3,763
3,866
3,908
- -
5,129
4,588
6,592
11,031
4,796
8,070
6,864
5,133
-4,179
-104,984
-160,438
Net Income, GAAP
33.49
31.16
31.17
34.16
40.66
- -
37.2
34.95
30.51
28.18
19.55
11
22.9
33.52
500.19
- -
- -
Effective Tax Rate (%)
8.1
8.03
6.86
6.01
5.03
- -
5.46
4.43
5.19
7.69
3.21
4.9
4.12
2.7
-2.22
-58.63
-87.73
Profit Margin (%)
5,825
4,307
4,145
7,959
23,356
- -
23,479
36,851
28,180
34,954
22,195
30,884
50,885
42,018
31,528
7,920
-21,597
Working Capital
1,360
2,895
5,469
4,565
7,438
- -
11,704
12,591
9,332
9,035
78,674
85,625
90,739
87,045
86,021
77,102
69,055
LT Debt
13,439
16,080
18,809
26,100
44,593
- -
48,810
66,195
74,487
81,270
83,171
87,542
116,323
117,169
112,435
13,773
-52,101
Total Equity
12.26
12.59
11.67
11.01
8.2
- -
14.65
5.77
7.04
8.98
3.29
4.48
2.79
0.77
-0.17
- -
- -
Return on Invested Capital (%)
12.12
13.82
11.82
10.48
8.93
- -
23.77
9.28
12.44
15.93
4.07
4.92
3.78
3.1
-3.31
- -
- -
Return on Capital (%)
25.13
25.93
24.07
19.67
14.09
- -
41.99
17.48
21.52
23.14
7.54
11.79
9.14
6.45
-5.4
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'23
Sep'23
Dec'23
ST Debt
101,771
129,138
134,082
LT Borrowings
74,293
71,808
69,055
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Jun'23
Sep'23
Dec'23
Total Current Assets
156,366
177,124
169,513
Cash, Cash Equivalents & STI
10,342
13,344
12,502
Accounts Receivable, Net
51,473
70,338
75,295
Inventories
90,238
87,127
77,867
Total Current Liabilities
157,838
182,556
191,110
Payables & Accruals
- -
- -
- -
ST Debt
101,771
129,138
134,082
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-10.58%
-87.75%
Free Cash Flow
- -
2,842.65%
183.7%
Net Income, GAAP
- -
451.78%
2,412.18%
Sales/Revenue/Turnover
- -
3.95%
-4.87%
Total Cash Common Dividend
- -
-12.4%
-66.42%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
45,265
44,365
49,214
49,373
188,218
2022
42,943
42,987
48,960
44,168
179,060
2023
47,062
44,188
47,462
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
4.54
-2.25
-5.66
- -
-65.17
2022
-3,777,000,000
-10,815,000,000
-1,110,000,000
- -
-104,984,000,000
2023
-4,200,000,000
-50,617,000,000
-16,341,000,000
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
14.03
0.97
14.7
- -
29.91
2022
594,000,000
47,000,000
1,000,000
- -
644,000,000
2023
- -
- -
- -
- -
- -
Similar Companies
Blau Farmacêutica S.A. (BLAU3.SA)
Nectar Lifesciences Limited (NECLIFE.NS)
Gour Medical S.A. (MLGML.PA)
Orexo AB (publ) (ORXOF)
Delta 9 Cannabis Inc. (DN.TO)
Jushi Holdings Inc. (JUSHF)
Business
Nichi-Iko Pharmaceutical Co., Ltd. operates as a pharmaceutical company primarily engaged in the manufacture and sale of generic drugs and related pharmaceutical products. Its core product portfolio includes generic pharmaceuticals across various therapeutic categories such as anti-infectives, steroids, cardiovascular drugs, central nervous system agents, and biosimilars. The company offers detailed product lines such as Sulpiride, Paroxetine, Olanzapine, Duloxetine, Memantine, Aciclovir, Betaxolol, Levofloxacin, Tacalcitol, Minocycline, Alfacalcidol, Warfarin Potassium, Filgrastim, Alendronate Sodium Hydrate, Raloxifene, Zoledronic Acid, Imatinib, and others. Nichi-Iko also engages in the development, manufacturing, and marketing of biosimilar products and operates multiple pharmaceutical manufacturing plants primarily based in Japan, with operations extending into North America and other markets. Founded in 1965 and headquartered in Gifu, Japan, Nichi-Iko Pharmaceutical serves healthcare providers and institutions primarily in Japan and overseas markets, focusing on both prescription generics and biosimilars. The company strategically expanded its global footprint through acquisitions, most notably the acquisition of Sagent Pharmaceuticals, a US-based pharmaceutical company, in a deal valued around $736 million, which significantly enhanced Nichi-Iko's production and marketing ability in North America. Additionally, Nichi-Iko divested from certain subsidiaries such as Sagent Pharmaceuticals and Omega Laboratories in early 2023 as part of its strategic portfolio realignment. Recently, Nichi-Iko has focused on digital transformation initiatives to improve pharmaceutical manufacturing processes. An ongoing collaboration with Fujitsu involves leveraging AI technology and digital tools to optimize manufacturing efficiency at its Gifu plant with plans to establish it as a model smart factory, aiming to replicate this across other manufacturing plants to ensure stable pharmaceutical supply. This digital initiative reflects the company's commitment to innovation and operational excellence in pharmaceutical production. Nichi-Iko operates in the pharmaceutical industry with segments including generic drugs, biosimilars, and pharmaceutical manufacturing services. Its target markets include hospitals, clinics, and healthcare providers across Japan and international markets, supported by a broad product portfolio and strategic alliances. The company continues to strengthen its financial position and market presence through operational improvements, strategic partnerships, and targeted acquisitions. Overall, Nichi-Iko Pharmaceutical Co., Ltd. is a leading Japanese generic pharmaceutical company offering a diverse product range from generic small molecule drugs to biosimilars, with significant recent moves in global expansion and digital manufacturing transformation focused on stable supply and growth in key markets like North America and Japan.